arrow
E

Elise Jirovec

university of helsinki
H指数:6
被引数:132

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Effects of Concomitant Medications on Clinical and Immunological Outcomes of Cancer Patients Treated With Oncolytic Adenoviruses

溶瘤腺病毒治疗癌症患者时联合用药对临床和免疫学结局的影响

2026-11-020
OAAI
Alistipes and Eggerthella shape the response to oncolytic adenovirus therapy in mice and humans through short-chain fatty acid metabolism

阿利斯特普斯菌和艾格特埃拉菌通过短链脂肪酸代谢塑造小鼠和人类对溶瘤腺病毒治疗的反应

2026-04-090
OA
Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors

单次静脉注射溶瘤腺病毒TILT-123可导致晚期实体瘤患者的全身肿瘤转导和免疫反应

2024-11-060
OAAI
Overcoming effector T cell exhaustion in ovarian cancer ascites with a novel adenovirus encoding for a MUC1 bispecific antibody engager and IL-2 cytokine

用编码MUC1双特异性抗体接合器和IL-2细胞因子的新型腺病毒克服卵巢癌腹水中的效应T细胞耗竭

2024-09-012
OAAI
Overcoming effector T cell exhaustion in ovarian cancer ascites with a novel adenovirus encoding for a MUC1 bispecific antibody engager and IL-2 cytokine (vol 32, 10.1016/j.ymthe.2024.06.029, 2024)
2024-08-010
OAAI
Immunological activity of oncolytic adenovirus encoding TNF α and IL-2 (TILT-123) in combination with pembrolizumab in platinum resistant or refractory ovarian cancer patients
2024-04-050
PRE
Safety, Efficacy, and Biological Data of T-Cell-Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial

TUNIMO单药治疗I期试验的晚期实体癌中T细胞使溶瘤腺病毒TILT-123的安全性,有效性和生物学数据

2024-03-274
OAAI
An oncolytic adenovirus coding for a variant interleukin 2 cytokine improves response to chemotherapy through enhancement of effector lymphocyte cytotoxicity, fibroblast compartment modulation and mitotic slippage

编码变异白介素2细胞因子的溶瘤腺病毒通过增强效应淋巴细胞的细胞毒性,成纤维细胞隔室调节和有丝分裂滑移来改善对化学疗法的反应

2023-07-053
OAAI
Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting

叙利亚仓鼠anti-PD-L1单克隆抗体的开发使溶瘤腺病毒免疫疗法能够在免疫能力病毒复制允许的环境中进行建模

2023-02-034
OAAI